There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas
and atypical adenomas. O 6-methyl-guanine-DNA methyltransferase is not the sole …

Context: Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic
agent for malignant gliomas. Recently, TMZ has been documented to be effective against …

Pituitary tumors are amongst the most common intracranial neoplasms and are generally
benign. However, some pituitary tumors exhibit clinically aggressive behavior that is …

BACKGROUND AND IMPORTANCE: The case presented here describes the clinical
evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently,
aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and …

BACKGROUND: Currently, no effective alternative treatment exists for progressive,
regrowing, nonfunctioning pituitary adenomas (NFPA) that are resistant to conventional …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded
to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable …

Temozolomide, an orally administered alkylating agent, is used to treat malignant gliomas.
Recent reports also have documented its efficacy in the treatment of pituitary adenomas and …